-
1
-
-
0036829823
-
Prevention of spread of hepatitis C
-
Alter MJ. Prevention of spread of hepatitis C. Hepatology. 2002;36:S93-S98.
-
(2002)
Hepatology
, vol.36
-
-
Alter, M.J.1
-
2
-
-
33646852746
-
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002.
-
Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705-714.
-
(2006)
Ann Intern Med.
, vol.144
, pp. 705-714
-
-
Armstrong, G.L.1
Wasley, A.2
Simard, E.P.3
-
3
-
-
22044433989
-
Natural history of hepatitis C
-
vi
-
Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis. 2005;9:383-398. vi.
-
(2005)
Clin Liver Dis.
, vol.9
, pp. 383-398
-
-
Thomas, D.L.1
Seeff, L.B.2
-
4
-
-
0034718227
-
The natural history of hepatitis C virus infection: Host, viral, and environmental factors
-
Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284:450-456.
-
(2000)
JAMA
, vol.284
, pp. 450-456
-
-
Thomas, D.L.1
Astemborski, J.2
Rai, R.M.3
-
5
-
-
0031972577
-
Hepatitis C viral infection in the immunosuppressed patient
-
Collier J, Heathcote J. Hepatitis C viral infection in the immunosuppressed patient. Hepatology. 1998;27:2-6.
-
(1998)
Hepatology
, vol.27
, pp. 2-6
-
-
Collier, J.1
Heathcote, J.2
-
6
-
-
0032969855
-
Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection
-
Lesens O, Deschenes M, Steben M, et al. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis. 1999;179:1254-1258.
-
(1999)
J Infect Dis.
, vol.179
, pp. 1254-1258
-
-
Lesens, O.1
Deschenes, M.2
Steben, M.3
-
7
-
-
0025807840
-
The significance of antibody to hepatitis C virus in patients with chronic hepatitis B
-
Fong TL, Di Bisceglie AM, Waggoner JG, et al. The significance of antibody to hepatitis C virus in patients with chronic hepatitis B. Hepatology. 1991;14:64-67.
-
(1991)
Hepatology
, vol.14
, pp. 64-67
-
-
Fong, T.L.1
Di Bisceglie, A.M.2
Waggoner, J.G.3
-
8
-
-
0034987263
-
Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity
-
Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2001;33: 1358-1364.
-
(2001)
Hepatology
, vol.33
, pp. 1358-1364
-
-
Adinolfi, L.E.1
Gambardella, M.2
Andreana, A.3
-
9
-
-
0031948693
-
Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis
-
DOI 10.1002/hep.510270404
-
Corrao G, Arico S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology. 1998;27: 914-919. (Pubitemid 28160474)
-
(1998)
Hepatology
, vol.27
, Issue.4
, pp. 914-919
-
-
Corrao, G.1
Arico, S.2
-
10
-
-
34250817672
-
Current indications and contraindications for liver transplantation
-
Ahmed A, Keeffe EB. Current indications and contraindications for liver transplantation. Clin Liver Dis. 2007; 11: 227-247.
-
(2007)
Clin Liver Dis.
, vol.11
, pp. 227-247
-
-
Ahmed, A.1
Keeffe, E.B.2
-
11
-
-
1842479859
-
Diagnosis, management, and treatment of hepatitis C
-
Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004; 39:1147-1171.
-
(2004)
Hepatology
, vol.39
, pp. 1147-1171
-
-
Strader, D.B.1
Wright, T.2
Thomas, D.L.3
-
12
-
-
0345416844
-
Therapy of hepatitis C: Meta-analysis of interferon alfa-2b trials
-
Carithers RL Jr, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology. 1997;26: 83S-88S.
-
(1997)
Hepatology
, vol.26
-
-
Carithers Jr., R.L.1
Emerson, S.S.2
-
13
-
-
0025203460
-
Molecular mechanisms of action of ribavirin
-
Patterson JL, Fernandez-Larsson R. Molecular mechanisms of action of ribavirin. Rev Infect Dis. 1990;12:1 139-1146.
-
(1990)
Rev Infect Dis.
, vol.12
, Issue.1
, pp. 139-1146
-
-
Patterson, J.L.1
Fernandez-Larsson, R.2
-
14
-
-
0032501714
-
Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. the Swedish Study Group
-
Reichard O, Norkrans G, Fryden A, et al. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet. 1998;351:83-87.
-
(1998)
Lancet
, vol.351
, pp. 83-87
-
-
Reichard, O.1
Norkrans, G.2
Fryden, A.3
-
16
-
-
0037179698
-
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
-
Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
-
(2002)
N Engl J Med.
, vol.347
, pp. 975-982
-
-
Fried, M.W.1
Shiffman, M.L.2
Reddy, K.R.3
-
17
-
-
0035934568
-
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
-
Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965.
-
(2001)
Lancet
, vol.358
, pp. 958-965
-
-
Manns, M.P.1
McHutchison, J.G.2
Gordon, S.C.3
-
18
-
-
42249091065
-
Early and sustained virological response in non-responders with chronic hepatitis C: A randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b
-
Scotto G, Fazio V, Fornabaio C, et al. Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b. Drugs. 2008; 68:791-801.
-
(2008)
Drugs
, vol.68
, pp. 791-801
-
-
Scotto, G.1
Fazio, V.2
Fornabaio, C.3
-
19
-
-
0036788338
-
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C
-
McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenter-ology. 2002;123:1061-1069.
-
(2002)
Gastroenterology
, vol.123
, pp. 1061-1069
-
-
McHutchison, J.G.1
Manns, M.2
Patel, K.3
-
20
-
-
14644393659
-
Neuropsy-chiatric adverse effects of interferon-alpha: Recognition and management
-
Raison CL, Demetrashvili M, Capuron L, et al. Neuropsy-chiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs. 2005;19:105-123.
-
(2005)
CNS Drugs
, vol.19
, pp. 105-123
-
-
Raison, C.L.1
Demetrashvili, M.2
Capuron, L.3
-
21
-
-
0035999141
-
Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C
-
Kraus MR, Schafer A, Faller H, et al. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther. 2002;16:1091-1099.
-
(2002)
Aliment Pharmacol Ther.
, vol.16
, pp. 1091-1099
-
-
Kraus, M.R.1
Schafer, A.2
Faller, H.3
-
22
-
-
10644237092
-
Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy
-
Pockros PJ, Shiffman ML, Schiff ER, et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology. 2004;40: 1450-1458.
-
(2004)
Hepatology
, vol.40
, pp. 1450-1458
-
-
Pockros, P.J.1
Shiffman, M.L.2
Schiff, E.R.3
-
23
-
-
11144358403
-
Epoetin alfa maintains ribavirin dose in HCV-infected patients: A prospective, double-blind, randomized controlled study
-
Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastro-enterology. 2004; 126:1302-1311.
-
(2004)
Gastro-enterology
, vol.126
, pp. 1302-1311
-
-
Afdhal, N.H.1
Dieterich, D.T.2
Pockros, P.J.3
-
24
-
-
68949119078
-
-
(cited December 2008); Available from:
-
Hepatitis C FAQs for health professionals. (cited December 2008); Available from: http://www.cdc.gov/hepatitis/HCV/ HCVfaq.htm#d4.
-
-
-
-
25
-
-
0033373404
-
Hepatitis C virus genotypes and quasispecies
-
Davis GL. Hepatitis C virus genotypes and quasispecies. Am J Med. 1999;107:21S-26S.
-
(1999)
Am J Med.
, vol.107
-
-
Davis, G.L.1
-
26
-
-
1542378867
-
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose
-
Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-355.
-
(2004)
Ann Intern Med.
, vol.140
, pp. 346-355
-
-
Hadziyannis, S.J.1
Sette Jr. H2
Morgan, T.R.3
-
27
-
-
9944257515
-
Meta-analysis: A randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4
-
Khuroo MS, Khuroo MS, Dahab ST. Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. Aliment Pharmacol Ther. 2004;20:931-938.
-
(2004)
Aliment Pharmacol Ther.
, vol.20
, pp. 931-938
-
-
Khuroo, M.S.1
Khuroo, M.S.2
Dahab, S.T.3
-
28
-
-
50549090087
-
Hepatitis C virus and kidney disease
-
Martin P, Fabrizi F. Hepatitis C virus and kidney disease. J Hepatol. 2008;49:613-624.
-
(2008)
J Hepatol..
, vol.49
, pp. 613-624
-
-
Martin, P.1
Fabrizi, F.2
-
29
-
-
34548673072
-
The impact of hepatitis C virus infection on survival in dialysis patients: Meta-analysis of observational studies
-
Fabrizi F, Takkouche B, Lunghi G, et al. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat. 2007;14:697-703.
-
(2007)
J Viral Hepat.
, vol.14
, pp. 697-703
-
-
Fabrizi, F.1
Takkouche, B.2
Lunghi, G.3
-
30
-
-
20544463615
-
Hepatitis C virus antibody status and survival after renal transplantation: Meta-analysis of observational studies
-
DOI 10.1111/j.1600-6143.2005.00864.x
-
Fabrizi F, Martin P, Dixit V, et al. Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant. 2005;5:1452-1461. (Pubitemid 40839438)
-
(2005)
American Journal of Transplantation
, vol.5
, Issue.6
, pp. 1452-1461
-
-
Fabrizi, F.1
Martin, P.2
Dixit, V.3
Bunnapradist, S.4
Dulai, G.5
-
31
-
-
0041663624
-
Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency
-
Bruchfeld A, Lindahl K, Stahle L, et al. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant. 2003; 18:1573-1580.
-
(2003)
Nephrol Dial Transplant.
, vol.18
, pp. 1573-1580
-
-
Bruchfeld, A.1
Lindahl, K.2
Stahle, L.3
-
32
-
-
0036890967
-
Dosage of ribavirin in patients with hepatitis C should be based on renal function: A population pharmacokinetic analysis
-
Bruchfeld A, Lindahl K, Schvarcz R, et al. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther Drug Monit. 2002;24:701-708.
-
(2002)
Ther Drug Monit.
, vol.24
, pp. 701-708
-
-
Bruchfeld, A.1
Lindahl, K.2
Schvarcz, R.3
-
33
-
-
33645969906
-
Pegylated interferon and ribavirin treatment for hepatitis C in haemo-dialysis patients
-
Bruchfeld A, Lindahl K, Reichard O, et al. Pegylated interferon and ribavirin treatment for hepatitis C in haemo-dialysis patients. J Viral Hepat. 2006;13:316-321.
-
(2006)
J Viral Hepat.
, vol.13
, pp. 316-321
-
-
Bruchfeld, A.1
Lindahl, K.2
Reichard, O.3
-
34
-
-
60749126501
-
Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of Hepatitis C in chronic kidney disease
-
Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of Hepatitis C in chronic kidney disease. Kidney International. 2008;73 (Suppl 109):S1-S99.
-
(2008)
Kidney International
, vol.73
, Issue.SUPPL. 109
-
-
-
35
-
-
11144310607
-
Meta-analysis: Effect of hepatitis C virus infection on mortality in dialysis
-
Fabrizi F, Martin P, Dixit V, et al. Meta-analysis: Effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther. 2004;20:1271-1277.
-
(2004)
Aliment Pharmacol Ther.
, vol.20
, pp. 1271-1277
-
-
Fabrizi, F.1
Martin, P.2
Dixit, V.3
-
36
-
-
0029070671
-
Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodia-lyzed patients
-
Pol S, Thiers V, Carnot F, et al. Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodia-lyzed patients. Kidney Int. 1995;47:1412-1418.
-
(1995)
Kidney Int.
, vol.47
, pp. 1412-1418
-
-
Pol, S.1
Thiers, V.2
Carnot, F.3
-
37
-
-
1642580512
-
Reversibility of hepatitis C virus-related cirrhosis
-
Pol S, Carnot F, Nalpas B, et al. Reversibility of hepatitis C virus-related cirrhosis. Hum Pathol. 2004;35:107-112.
-
(2004)
Hum Pathol.
, vol.35
, pp. 107-112
-
-
Pol, S.1
Carnot, F.2
Nalpas, B.3
-
38
-
-
7044231396
-
Hepatocellular carcinoma: Recent trends in the United States
-
El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004;127:S27-S34.
-
(2004)
Gastroenterology
, vol.127
-
-
El-Serag, H.B.1
-
39
-
-
2442665224
-
Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites
-
Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004;350: 2265-2271.
-
(2004)
N Engl J Med.
, vol.350
, pp. 2265-2271
-
-
Muir, A.J.1
Bornstein, J.D.2
Killenberg, P.G.3
-
40
-
-
33746535101
-
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1
-
Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. 2006; 131:470-477.
-
(2006)
Gastroenterology
, vol.131
, pp. 470-477
-
-
Conjeevaram, H.S.1
Fried, M.W.2
Jeffers, L.J.3
-
41
-
-
33947644908
-
Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3
-
Shiffman ML, Mihas AA, Millwala F, et al. Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3. Am J Gastroenterol. 2007;102:761-766.
-
(2007)
Am J Gastroenterol.
, vol.102
, pp. 761-766
-
-
Shiffman, M.L.1
Mihas, A.A.2
Millwala, F.3
-
42
-
-
84869982394
-
Virologic responses to pegIFN-2a/ribavirin in treatment-naive Latino versus non-Latino Caucasians infected with HCV genotype 1: The LATINO study
-
San Diego, CA
-
Rodriguez-Torres M, Jeffers LJ, Sheikh MY, et al. Virologic responses to pegIFN-2a/ribavirin in treatment-naive Latino versus non-Latino Caucasians infected with HCV genotype 1: The LATINO study. DDW. San Diego, CA; 2008.
-
(2008)
DDW
-
-
Rodriguez-Torres, M.1
Jeffers, L.J.2
Sheikh, M.Y.3
-
43
-
-
40949151098
-
Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C
-
Romero-Gomez M, Fernandez-Rodriguez CM, Andrade RJ, et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol. 2008;48:721-727.
-
(2008)
J Hepatol.
, vol.48
, pp. 721-727
-
-
Romero-Gomez, M.1
Fernandez-Rodriguez, C.M.2
Andrade, R.J.3
-
44
-
-
0037087144
-
Hepatitis C Virus prevalence among patients infected with human immunodeficiency virus: A cross-sectional analysis of the US adult AIDS clinical trials group
-
Sherman KE, Rouster SD, Chung RT, et al. Hepatitis C Virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS clinical trials group. Clin Infect Dis. 2002;34:831-837.
-
(2002)
Clin Infect Dis.
, vol.34
, pp. 831-837
-
-
Sherman, K.E.1
Rouster, S.D.2
Chung, R.T.3
-
45
-
-
0035112776
-
Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection
-
Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32: 492-497.
-
(2001)
Clin Infect Dis.
, vol.32
, pp. 492-497
-
-
Bica, I.1
McGovern, B.2
Dhar, R.3
-
46
-
-
0035882187
-
Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis
-
Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33: 562-569.
-
(2001)
Clin Infect Dis.
, vol.33
, pp. 562-569
-
-
Graham, C.S.1
Baden, L.R.2
Yu, E.3
-
47
-
-
3343012408
-
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients
-
Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438-450.
-
(2004)
N Engl J Med.
, vol.351
, pp. 438-450
-
-
Torriani, F.J.1
Rodriguez-Torres, M.2
Rockstroh, J.K.3
-
48
-
-
3343006133
-
Risk factors for hepatic decompensation in patients with HIV/HCV coinfec-tion and liver cirrhosis during interferon-based therapy
-
Mauss S, Valenti W, DePamphilis J, et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfec-tion and liver cirrhosis during interferon-based therapy. AIDS. 2004;18:F21-F25.
-
(2004)
AIDS
, vol.18
-
-
Mauss, S.1
Valenti, W.2
Depamphilis, J.3
-
49
-
-
33748751179
-
Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons
-
Alvarez D, Dieterich DT, Brau N, et al. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat. 2006; 13:683-689.
-
(2006)
J Viral Hepat.
, vol.13
, pp. 683-689
-
-
Alvarez, D.1
Dieterich, D.T.2
Brau, N.3
-
50
-
-
68949084536
-
Rapid Virologic response to peginterferon alfa and ribavirin treatment of chronic hepatitis C predicts sustained virologic response and relapse
-
San Diego, CA
-
Poordad F, Kambili C. Rapid Virologic response to peginterferon alfa and ribavirin treatment of chronic hepatitis C predicts sustained virologic response and relapse. DDW. San Diego, CA.
-
DDW
-
-
Poordad, F.1
Kambili, C.2
-
51
-
-
68949089588
-
Rapid virlogical response is a more important predictor of sustained viro-logical response (SVR) than genotype in patients with chronic hepatitis C infection.
-
Milan, Italy
-
Fried M, Hadziyannis SJ, Shiffman M, et al. Rapid virlogical response is a more important predictor of sustained viro-logical response (SVR) than genotype in patients with chronic hepatitis C infection. EASL. Milan, Italy; 2008.
-
(2008)
EASL
-
-
Fried, M.1
Hadziyannis, S.J.2
Shiffman, M.3
-
52
-
-
33646590308
-
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kD)/ribavirin therapy
-
Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kD)/ribavirin therapy. Hepatology. 2006;43:954-960.
-
(2006)
Hepatology
, vol.43
, pp. 954-960
-
-
Jensen, D.M.1
Morgan, T.R.2
Marcellin, P.3
-
53
-
-
34250320980
-
Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin
-
Yu JW, Wang GQ, Sun LJ, et al. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol. 2007;22:832-836.
-
(2007)
J Gastroenterol Hepatol
, vol.22
, pp. 832-836
-
-
Yu, J.W.1
Wang, G.Q.2
Sun, L.J.3
-
54
-
-
23444460553
-
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40kD)/ribavirin
-
Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40kD)/ribavirin. J Hepatol. 2005;43:425-433.
-
(2005)
J Hepatol.
, vol.43
, pp. 425-433
-
-
Ferenci, P.1
Fried, M.W.2
Shiffman, M.L.3
-
55
-
-
28844451934
-
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia
-
Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol. 2006;44:97-103.
-
(2006)
Hepatol.
, vol.44
, pp. 97-103
-
-
Zeuzem, S.1
Buti, M.2
Ferenci, P.3
-
56
-
-
23244457832
-
Peginterferon-alpha-2a (40 kD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C
-
von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha-2a (40 kD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology. 2005; 129:522-527.
-
(2005)
Gastroenterology
, vol.129
, pp. 522-527
-
-
Von Wagner, M.1
Huber, M.2
Berg, T.3
-
57
-
-
34147207791
-
A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C
-
Yu ML, Dai CY, Huang JF, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut. 2007;56:553-559.
-
(2007)
Gut.
, vol.56
, pp. 553-559
-
-
Yu, M.L.1
Dai, C.Y.2
Huang, J.F.3
-
58
-
-
20544443172
-
Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3
-
DOI 10.1056/NEJMoa042608
-
Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 versus 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005;352:2609-2617. (Pubitemid 41007847)
-
(2005)
New England Journal of Medicine
, vol.352
, Issue.25
, pp. 2609-2617
-
-
Mangia, A.1
Santoro, R.2
Minerva, N.3
Ricci, G.L.4
Carretta, V.5
Persico, M.6
Vinelli, F.7
Scotto, G.8
Bacca, D.9
Annese, M.10
Romano, M.11
Zechini, F.12
Sogari, F.13
Spirito, F.14
Andriulli, A.15
-
59
-
-
34447318385
-
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3
-
Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2007;357:124-134.
-
(2007)
N Engl J Med.
, vol.357
, pp. 124-134
-
-
Shiffman, M.L.1
Suter, F.2
Bacon, B.R.3
-
60
-
-
0041822106
-
Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C
-
Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003;38:645-652.
-
(2003)
Hepatology
, vol.38
, pp. 645-652
-
-
Davis, G.L.1
Wong, J.B.2
McHutchison, J.G.3
-
61
-
-
84855715360
-
Differentiation of early virologic response (EVR) into RVR complete EVR (cEVR) and partial EVR (pEVR) allows for a more precise prediction of SVR in HCV genotype 1 patients treated with peginterferon alfa-2a (40kD) (PEGASYSs) and ribavirin.
-
Boston
-
Marcellin P, Jensen D, Hadziyannis J, et al. Differentiation of early virologic response (EVR) into RVR, complete EVR (cEVR) and partial EVR (pEVR) allows for a more precise prediction of SVR in HCV genotype 1 patients treated with peginterferon alfa-2a (40kD) (PEGASYSs) and ribavirin. AASLD. Boston peginterferon alfa-2a (40kD) (PEGASYSs) and ribavirin. AASLD. Boston 2007.
-
(2007)
AASLD.
-
-
Marcellin, P.1
Jensen, D.2
Hadziyannis, J.3
-
62
-
-
33847198680
-
Pegylated interferon and ribavirin failures: Is retreatment an option
-
Cheruvattath R, Rosati MJ, Gautam M, et al. Pegylated interferon and ribavirin failures: is retreatment an option? Dig Dis Sci. 2007;52:732-736.
-
(2007)
Dig Dis Sci.
, vol.52
, pp. 732-736
-
-
Cheruvattath, R.1
Rosati, M.J.2
Gautam, M.3
-
63
-
-
30344483613
-
Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: A randomized open-label pilot study
-
Cornberg M, Hadem J, Herrmann E, et al. Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study. J Hepatol. 2006;44:291-301.
-
(2006)
J Hepatol.
, vol.44
, pp. 291-301
-
-
Cornberg, M.1
Hadem, J.2
Herrmann, E.3
-
64
-
-
33644646748
-
A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C
-
Jacobson IM, Gonzalez SA, Ahmed F, et al. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol. 2005;100:2453-2462.
-
(2005)
Am J Gastroenterol.
, vol.100
, pp. 2453-2462
-
-
Jacobson, I.M.1
Gonzalez, S.A.2
Ahmed, F.3
-
65
-
-
51249090533
-
Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C
-
Maylin S, Martinot-Peignoux M, Moucari R, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology. 2008;135:821-829.
-
(2008)
Gastroenterology
, vol.135
, pp. 821-829
-
-
Maylin, S.1
Martinot-Peignoux, M.2
Moucari, R.3
-
66
-
-
68949119077
-
Clearance of HCV at 5 year follow-up for peginterferon alfa-2b ± ribavirin is predicted by sustained virologic response at 24 weeks post treatment
-
San Diego, CA
-
Lindsay K, Manns M, Gordon S, et al. Clearance of HCV at 5 year follow-up for peginterferon alfa-2b ± ribavirin is predicted by sustained virologic response at 24 weeks post treatment. DDW. San Diego, CA; 2008.
-
(2008)
DDW
-
-
Lindsay, K.1
Manns, M.2
Gordon, S.3
-
67
-
-
68949144238
-
Durability of sustained virologic response in combination therapy with interferon/peginterfer-on and ribavirin for chronic hepatitis C
-
San Francisco;
-
Lee J, Lee J, Kim Y, et al. Durability of sustained virologic response in combination therapy with interferon/peginterfer-on and ribavirin for chronic hepatitis C. AASLD. San Francisco; 2008.
-
(2008)
AASLD
-
-
Lee, J.1
Lee, J.2
Kim, Y.3
-
68
-
-
4644308691
-
Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy
-
Veldt BJ, Saracco G, Boyer N, et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut. 2004;53: 1504-1508.
-
(2004)
Gut.
, vol.53
, pp. 1504-1508
-
-
Veldt, B.J.1
Saracco, G.2
Boyer, N.3
-
69
-
-
0033058754
-
Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon
-
DOI 10.1016/S0168-8278(99)80129-9
-
Reichard O, Glaumann H, Fryden A, et al. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J Hepatol. 1999;30:783-787. (Pubitemid 29248976)
-
(1999)
Journal of Hepatology
, vol.30
, Issue.5
, pp. 783-787
-
-
Reichard, O.1
Glaumann, H.2
Fryden, A.3
Norkrans, G.4
Wejstal, R.5
Weiland, O.6
-
70
-
-
15644380122
-
Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy
-
Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med. 1997;127:875-881.
-
(1997)
Ann Intern Med.
, vol.127
, pp. 875-881
-
-
Marcellin, P.1
Boyer, N.2
Gervais, A.3
-
71
-
-
34447545514
-
Long-term follow-up of the hepatitis C HENCORE cohort: Response to therapy and occurrence of liver-related complications
-
Pradat P, Tillmann HL, Sauleda S, et al. Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications. J Viral Hepat. 2007;14:556-563.
-
(2007)
J Viral Hepat
, vol.14
, pp. 556-563
-
-
Pradat, P.1
Tillmann, H.L.2
Sauleda, S.3
-
72
-
-
50849095496
-
Immune suppression leading to hepatitis C virus re-emergence after sustained virological response
-
Lin A, Thadareddy A, Goldstein MJ, et al. Immune suppression leading to hepatitis C virus re-emergence after sustained virological response. J Med Virol. 2008;80: 1720-1722.
-
(2008)
J Med Virol.
, vol.80
, pp. 1720-1722
-
-
Lin, A.1
Thadareddy, A.2
Goldstein, M.J.3
-
73
-
-
51449097767
-
Recurrence of HCV infection in a sustained responder after chemotherapy for non-Hodgkin's lymphoma: Successful retreatment
-
Thomopoulos K, Giannakoulas NC, Tsamandas AC, et al. Recurrence of HCV infection in a sustained responder after chemotherapy for non-Hodgkin's lymphoma: successful retreatment. Am J Med Sci. 2008;336:73-76.
-
(2008)
Am J Med Sci.
, vol.336
, pp. 73-76
-
-
Thomopoulos, K.1
Giannakoulas, N.C.2
Tsamandas, A.C.3
-
74
-
-
0029054011
-
A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter study group
-
Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter study group. N Engl J Med. 1995;332:1457-1462.
-
(1995)
N Engl J Med.
, vol.332
, pp. 1457-1462
-
-
Poynard, T.1
Bedossa, P.2
Chevallier, M.3
-
75
-
-
0036242165
-
Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C
-
Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122: 1303-1313.
-
(2002)
Gastroenterology
, vol.122
, pp. 1303-1313
-
-
Poynard, T.1
McHutchison, J.2
Manns, M.3
-
76
-
-
10744232465
-
Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: A meta-analysis of individual patient data
-
Camma C, Di Bona D, Schepis F, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology. 2004;39:333-342.
-
(2004)
Hepatology
, vol.39
, pp. 333-342
-
-
Camma, C.1
Di Bona, D.2
Schepis, F.3
-
77
-
-
0034619980
-
Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis
-
Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 2000;343:1673-1680.
-
(2000)
N Engl J Med.
, vol.343
, pp. 1673-1680
-
-
Heathcote, E.J.1
Shiffman, M.L.2
Cooksley, W.G.3
-
78
-
-
33750959362
-
Sustained virological response following HCV therapy is associated with non-progression of liver fibrosis in HCV/HIV-coinfected patients
-
Barreiro P, Labarga P, Martin-Carbonero L, et al. Sustained virological response following HCV therapy is associated with non-progression of liver fibrosis in HCV/HIV-coinfected patients. Antivir Ther. 2006; 11:869-877.
-
(2006)
Antivir Ther.
, vol.11
, pp. 869-877
-
-
Barreiro, P.1
Labarga, P.2
Martin-Carbonero, L.3
-
79
-
-
33947360829
-
Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: A retrospective study
-
Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45:579-587.
-
(2007)
Hepatology
, vol.45
, pp. 579-587
-
-
Bruno, S.1
Stroffolini, T.2
Colombo, M.3
-
80
-
-
35648970573
-
Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin
-
Braks RE, Ganne-Carrie N, Fontaine H, et al. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastro-enterol. 2007;13:5648-5653.
-
(2007)
World J Gastro-enterol.
, vol.13
, pp. 5648-5653
-
-
Braks, R.E.1
Ganne-Carrie, N.2
Fontaine, H.3
-
81
-
-
68949134802
-
Effect of sustained virological response to pedinterferon plus ribavirin therapy on liver related free survival in HCV cirrhotic patients. Factors predicting virological response.
-
San Francisco
-
Alonso S, Rincón D, Bárcena R, et al. Effect of sustained virological response to pedinterferon plus ribavirin therapy on liver related free survival in HCV cirrhotic patients. Factors predicting virological response. AASLD. San Francisco.
-
AASLD
-
-
Alonso, S.1
Rincón, D.2
Bárcena, R.3
-
82
-
-
68949103186
-
Lower risk of hepatocellular carcinoma and improved survival in patients with HCV related cirrhosis with sustained Virological response
-
San Francisco
-
Cardoso AF, Moucari R, Giuily N, et al. Lower risk of hepatocellular carcinoma and improved survival in patients with HCV related cirrhosis with sustained Virological response AASLD. San Francisco; 2008.
-
(2008)
AASLD
-
-
Cardoso, A.F.1
Moucari, R.2
Giuily, N.3
-
83
-
-
38449091418
-
Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis
-
Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007; 147:677-684.
-
(2007)
Ann Intern Med.
, vol.147
, pp. 677-684
-
-
Veldt, B.J.1
Heathcote, E.J.2
Wedemeyer, H.3
-
84
-
-
0033520109
-
Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy
-
Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med. 1999;131:174-181.
-
(1999)
Ann Intern Med.
, vol.131
, pp. 174-181
-
-
Yoshida, H.1
Shiratori, Y.2
Moriyama, M.3
-
85
-
-
17344369924
-
Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group
-
Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology. 1998;27:1394-1402.
-
(1998)
Hepatology
, vol.27
, pp. 1394-1402
-
-
Kasahara, A.1
Hayashi, N.2
Mochizuki, K.3
-
86
-
-
0343111507
-
Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka hepatocellular Carcinoma prevention study group.
-
Imai Y, Kawata S, Tamura S, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka hepatocellular Carcinoma prevention study group. Ann Intern Med. 1998;129:94-99.
-
(1998)
Ann Intern Med.
, vol.129
, pp. 94-99
-
-
Imai, Y.1
Kawata, S.2
Tamura, S.3
-
87
-
-
0035915622
-
Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis.
-
Nishiguchi S, Shiomi S, Nakatani S, et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet. 2001 ;357:196-197.
-
(2001)
Lancet.
, vol.357
, pp. 196-197
-
-
Nishiguchi, S.1
Shiomi, S.2
Nakatani, S.3
-
88
-
-
68949111344
-
Long-term efficacy of peginterferon with ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related advanced fibrosis
-
San Francisco
-
Chang K, Lee C, Wang J, et al. Long-term efficacy of peginterferon with ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related advanced fibrosis. AASLD. San Francisco; 2008.
-
(2008)
AASLD
-
-
Chang, K.1
Lee, C.2
Wang, J.3
-
89
-
-
56349165583
-
Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients
-
Hirakawa M, Ikeda K, Arase Y, et al. Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients. Intern Med. 2008;47:1637-1643.
-
(2008)
Intern Med.
, vol.47
, pp. 1637-1643
-
-
Hirakawa, M.1
Ikeda, K.2
Arase, Y.3
-
90
-
-
34948827036
-
Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C
-
Tanaka A, Uegaki S, Kurihara H, et al. Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C. World J Gastroenterol. 2007;13:5180-5187.
-
(2007)
World J Gastroenterol.
, vol.13
, pp. 5180-5187
-
-
Tanaka, A.1
Uegaki, S.2
Kurihara, H.3
-
91
-
-
59849093175
-
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease
-
Lok AS, Seeff LB, Morgan TR, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009;136:138-148.
-
(2009)
Gastroenterology
, vol.136
, pp. 138-148
-
-
Lok, A.S.1
Seeff, L.B.2
Morgan, T.R.3
-
92
-
-
0034070192
-
HCV-related fibrosis progression following liver transplantation: Increase in recent years
-
Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol. 2000;32:673-684.
-
(2000)
J Hepatol.
, vol.32
, pp. 673-684
-
-
Berenguer, M.1
Ferrell, L.2
Watson, J.3
-
93
-
-
0037080560
-
Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft
-
Sanchez-Fueyo A, Restrepo JC, Quinto L, et al. Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation. 2002;73:56-63.
-
(2002)
Transplantation.
, vol.73
, pp. 56-63
-
-
Sanchez-Fueyo, A.1
Restrepo, J.C.2
Quinto, L.3
-
94
-
-
34547455714
-
A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation
-
Yilmaz N, Shiffman ML, Stravitz RT, et al. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl. 2007;13:975-983.
-
(2007)
Liver Transpl.
, vol.13
, pp. 975-983
-
-
Yilmaz, N.1
Shiffman, M.L.2
Stravitz, R.T.3
-
95
-
-
0036245493
-
A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation
-
Crippin JS, McCashland T, Terrault N, et al. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl. 2002;8:350-355.
-
(2002)
Liver Transpl.
, vol.8
, pp. 350-355
-
-
Crippin, J.S.1
McCashland, T.2
Terrault, N.3
-
96
-
-
10744234013
-
Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation
-
Forns X, Garcia-Retortillo M, Serrano T, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol. 2003;39:389-396.
-
(2003)
J Hepatol.
, vol.39
, pp. 389-396
-
-
Forns, X.1
Garcia-Retortillo, M.2
Serrano, T.3
-
97
-
-
23044500773
-
Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy
-
Everson GT, Trotter J, Forman L, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology. 2005;42: 255-262.
-
(2005)
Hepatology
, vol.42
, pp. 255-262
-
-
Everson, G.T.1
Trotter, J.2
Forman, L.3
-
98
-
-
17344367725
-
The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation
-
Sheiner PA, Boros P, Klion FM, et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology. 1998;28: 831-838.
-
(1998)
Hepatology
, vol.28
, pp. 831-838
-
-
Sheiner, P.A.1
Boros, P.2
Klion, F.M.3
-
99
-
-
19944430229
-
Peginterferon Alfa-2a for hepatitis C after liver transplantation: Two randomized, controlled trials
-
DOI 10.1002/hep.20560
-
Chalasani N, Manzarbeitia C, Ferenci P, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology. 2005;41:289-298. (Pubitemid 40165372)
-
(2005)
Hepatology
, vol.41
, Issue.2
, pp. 289-298
-
-
Chalasani, N.1
Manzarbeitia, C.2
Ferenci, P.3
Vogel, W.4
Fontana, R.J.5
Voigt, M.6
Riely, C.7
Martin, P.8
Teperman, L.9
Jiao, J.10
Lopez-Talavera, J.C.11
-
100
-
-
0035077063
-
Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment
-
Mazzaferro V, Tagger A, Schiavo M, et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transplant Proc. 2001;33:1355-1357.
-
(2001)
Transplant Proc.
, vol.33
, pp. 1355-1357
-
-
Mazzaferro, V.1
Tagger, A.2
Schiavo, M.3
-
101
-
-
3242780201
-
Outcomes of acute rejection after interferon therapy in liver transplant recipients
-
Saab S, Kalmaz D, Gajjar NA, et al. Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver Transpl. 2004;10:859-867.
-
(2004)
Liver Transpl.
, vol.10
, pp. 859-867
-
-
Saab, S.1
Kalmaz, D.2
Gajjar, N.A.3
-
102
-
-
34247863801
-
Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: A randomized controlled study
-
Carrion JA, Navasa M, Garcia-Retortillo M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology. 2007; 132:1746-1756.
-
(2007)
Gastroenterology
, vol.132
, pp. 1746-1756
-
-
Carrion, J.A.1
Navasa, M.2
Garcia-Retortillo, M.3
-
103
-
-
34247605934
-
A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C
-
Angelico M, Petrolati A, Lionetti R, et al. A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol. 2007;46:1009-1017.
-
(2007)
J Hepatol.
, vol.46
, pp. 1009-1017
-
-
Angelico, M.1
Petrolati, A.2
Lionetti, R.3
-
104
-
-
3242888585
-
Hepatitis C virus-related extra-hepatic disease-aetiopathogenesis and management
-
Medina J, Garcia-Buey L, Moreno-Otero R. Hepatitis C virus-related extra-hepatic disease-aetiopathogenesis and management. Aliment Pharmacol Ther. 2004;20:129-141.
-
(2004)
Aliment Pharmacol Ther.
, vol.20
, pp. 129-141
-
-
Medina, J.1
Garcia-Buey, L.2
Moreno-Otero, R.3
-
105
-
-
0033979549
-
Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. the GERMI-VIC. Groupe d'Etude et de Recherche en medecine interne et maladies infectieuses sur le virus de l'Hepatite C
-
Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMI-VIC. Groupe d'Etude et de Recherche en medecine interne et maladies infectieuses sur le virus de l'Hepatite C. Medicine (Baltimore). 2000;79:47-56.
-
(2000)
Medicine (Baltimore)
, vol.79
, pp. 47-56
-
-
Cacoub, P.1
Renou, C.2
Rosenthal, E.3
-
106
-
-
0028198592
-
Immunological disorders in C virus chronic active hepatitis: A prospective case-control study
-
Pawlotsky JM, Ben Yahia M, Andre C, et al. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology. 1994;19:841-848.
-
(1994)
Hepatology
, vol.19
, pp. 841-848
-
-
Pawlotsky, J.M.1
Ben Yahia, M.2
Andre, C.3
-
107
-
-
0032855572
-
Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia
-
Calleja JL, Albillos A, Moreno-Otero R, et al. Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia. Aliment Pharmacol Ther. 1999;13: 1179-1186.
-
(1999)
Aliment Pharmacol Ther.
, vol.13
, pp. 1179-1186
-
-
Calleja, J.L.1
Albillos, A.2
Moreno-Otero, R.3
-
108
-
-
0033818316
-
Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha
-
Zuckerman E, Keren D, Slobodin G, et al. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha. J Rheumatol. 2000;27:2172-2178.
-
(2000)
J Rheumatol.
, vol.27
, pp. 2172-2178
-
-
Zuckerman, E.1
Keren, D.2
Slobodin, G.3
-
109
-
-
0032813308
-
Fatal exacerbation of hepatitis C-related cryoglobulinemia with interferon-alpha therapy
-
Friedman G, Mehta S, Sherker AH. Fatal exacerbation of hepatitis C-related cryoglobulinemia with interferon-alpha therapy. Dig Dis Sci. 1999;44:1364-1365.
-
(1999)
Dig Dis Sci.
, vol.44
, pp. 1364-1365
-
-
Friedman, G.1
Mehta, S.2
Sherker, A.H.3
-
110
-
-
30844446978
-
Effects of combined antiviral therapy on asymptomatic mixed cryoglobulinemia in naive patients with chronic hepatitis C virus infection: A preliminary study
-
D'Amico E, Chincoli C, Cacciatore P, et al. Effects of combined antiviral therapy on asymptomatic mixed cryoglobulinemia in naive patients with chronic hepatitis C virus infection: a preliminary study. Dig Dis Sci. 2005;50: 2344-2347.
-
(2005)
Dig Dis Sci.
, vol.50
, pp. 2344-2347
-
-
D'Amico, E.1
Chincoli, C.2
Cacciatore, P.3
-
111
-
-
0037332040
-
Renal manifestations of hepatitis C virus infection. Extrahepatic complications often are silent-and thus overlooked
-
86
-
Bandi L. Renal manifestations of hepatitis C virus infection. Extrahepatic complications often are silent-and thus overlooked. Postgrad Med. 2003; 113:73-76, 86.
-
(2003)
Postgrad Med.
, vol.113
, pp. 73-76
-
-
Bandi, L.1
-
112
-
-
0027233971
-
Membranous glomerulonephritis in association with hepatitis C virus infection
-
Davda R, Peterson J, Weiner R, et al. Membranous glomerulonephritis in association with hepatitis C virus infection. Am J Kidney Dis. 1993;22:452-455.
-
(1993)
Am J Kidney Dis.
, vol.22
, pp. 452-455
-
-
Davda, R.1
Peterson, J.2
Weiner, R.3
-
113
-
-
0038188594
-
Hepatitis C virus-related cryoglobulinemic glomerulonephritis: Long-term remission after antiviral therapy
-
Rossi P, Bertani T, Baio P, et al. Hepatitis C virus-related cryoglobulinemic glomerulonephritis: long-term remission after antiviral therapy. Kidney Int. 2003;63:2236-2241.
-
(2003)
Kidney Int.
, vol.63
, pp. 2236-2241
-
-
Rossi, P.1
Bertani, T.2
Baio, P.3
-
114
-
-
0037109603
-
Interferon alpha and ribavirin for membranoproliferative glomerulonephritis and hepatitis C infection
-
Loustaud-Ratti V, Liozon E, Karaaslan H, et al. Interferon alpha and ribavirin for membranoproliferative glomerulonephritis and hepatitis C infection. Am J Med. 2002; 113: 516-519.
-
(2002)
Am J Med.
, vol.113
, pp. 516-519
-
-
Loustaud-Ratti, V.1
Liozon, E.2
Karaaslan, H.3
-
115
-
-
0032972998
-
Successful treatment of HCV-associated cryoglobulinaemic glomerulonephritis with a combination of interferon-alpha and ribavirin
-
Misiani R, Bellavita P, Baio P, et al. Successful treatment of HCV-associated cryoglobulinaemic glomerulonephritis with a combination of interferon-alpha and ribavirin. Nephrol Dial Transplant. 1999;14:1558-1560.
-
(1999)
Nephrol Dial Transplant.
, vol.14
, pp. 1558-1560
-
-
Misiani, R.1
Bellavita, P.2
Baio, P.3
-
116
-
-
0141674800
-
Prevalence of hepatitis C virus infection in porphyria cutanea tarda: Systematic review and meta-analysis
-
DOI 10.1016/S0168-8278(03)00346-5
-
Gisbert JP, Garcia-Buey L, Pajares JM, et al. Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol. 2003;39: 620-627. (Pubitemid 37204664)
-
(2003)
Journal of Hepatology
, vol.39
, Issue.4
, pp. 620-627
-
-
Gisbert, J.P.1
Garcia-Buey, L.2
Pajares, J.M.3
Moreno-Otero, R.4
-
117
-
-
0028969640
-
Normalization of urinary porphyrin level and disappearance of skin lesions after successful interferon therapy in a case of chronic hepatitis C complicated with porphyria cutanea tarda
-
Takikawa H, Yamazaki R, Shoji S, et al. Normalization of urinary porphyrin level and disappearance of skin lesions after successful interferon therapy in a case of chronic hepatitis C complicated with porphyria cutanea tarda. J Hepatol. 1995;22:249-250.
-
(1995)
J Hepatol.
, vol.22
, pp. 249-250
-
-
Takikawa, H.1
Yamazaki, R.2
Shoji, S.3
-
118
-
-
15444345904
-
Dramatic resolution of skin lesions associated with porphyria cutanea tarda after interferon-alpha therapy in a case of chronic hepatitis C
-
Sheikh MY, Wright RA, Burruss JB. Dramatic resolution of skin lesions associated with porphyria cutanea tarda after interferon-alpha therapy in a case of chronic hepatitis C. Dig Dis Sci. 1998;43:529-533.
-
(1998)
Dig Dis Sci.
, vol.43
, pp. 529-533
-
-
Sheikh, M.Y.1
Wright, R.A.2
Burruss, J.B.3
-
119
-
-
33845489288
-
Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection
-
DOI 10.2337/dc06-0456
-
Simo R, Lecube A, Genesca J, et al. Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. Diabetes Care. 2006;29:2462-2466. (Pubitemid 44912253)
-
(2006)
Diabetes Care
, vol.29
, Issue.11
, pp. 2462-2466
-
-
Simo, R.1
Lecube, A.2
Genesca, J.3
Esteban, J.I.4
Hernandez, C.5
-
120
-
-
0036623222
-
Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis
-
Cacoub P, Ratziu V, Myers RP, et al. Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C.J Hepatol. 2002;36:812-818.
-
(2002)
C.J Hepatol.
, vol.36
, pp. 812-818
-
-
Cacoub, P.1
Ratziu, V.2
Myers, R.P.3
-
121
-
-
0031941455
-
A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C
-
Bayliss MS, Gandek B, Bungay KM, et al. A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Qual Life Res. 1998;7: 39-55.
-
(1998)
Qual Life Res.
, vol.7
, pp. 39-55
-
-
Bayliss, M.S.1
Gandek, B.2
Bungay, K.M.3
-
122
-
-
33947425672
-
The effects of HCV infection and management on health-related quality of life
-
DOI 10.1002/hep.21565
-
Younossi Z, Kallman J, Kincaid J. The effects of HCV infection and management on health-related quality of life. Hepatology. 2007;45:806-816. (Pubitemid 46450632)
-
(2007)
Hepatology
, vol.45
, Issue.3
, pp. 806-816
-
-
Younossi, Z.1
Kallman, J.2
Kincaid, J.3
-
123
-
-
33846828559
-
Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis
-
Bonkovsky HL, Snow KK, Malet PF, et al. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol. 2007;46:420-431.
-
(2007)
J Hepatol.
, vol.46
, pp. 420-431
-
-
Bonkovsky, H.L.1
Snow, K.K.2
Malet, P.F.3
-
124
-
-
16244391099
-
Impact of hepatitis Con health related quality of life: A systematic review and quantitative assessment
-
Spiegel BM, Younossi ZM, Hays RD, et al. Impact of hepatitis Con health related quality of life: a systematic review and quantitative assessment. Hepatology. 2005;41:790-800.
-
(2005)
Hepatology
, vol.41
, pp. 790-800
-
-
Spiegel, B.M.1
Younossi, Z.M.2
Hays, R.D.3
-
125
-
-
8444252118
-
Nonresponders to hepatitis C virus antiviral therapy: Pegylated interferons and beyond
-
viii
-
Fontana RJ. Nonresponders to hepatitis C virus antiviral therapy: pegylated interferons and beyond. Gastroenterol Clin North Am. 2004;33:527-547. viii.
-
(2004)
Gastroenterol Clin North Am.
, vol.33
, pp. 527-547
-
-
Fontana, R.J.1
-
126
-
-
57349116772
-
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon
-
Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med. 2008;359:2429-2441.
-
(2008)
N Engl J Med.
, vol.359
, pp. 2429-2441
-
-
Di Bisceglie, A.M.1
Shiffman, M.L.2
Everson, G.T.3
|